Single Patient Use of ION-682884 for a Patient with Transthyretin Mediated Amyloid Cardiomyopathy
N
Noel Dasgupta
Primary Investigator
Overview
This study is being done to help potentially improve or stabilize heart failure related to transthyretin amyloidosis. The plan is to administer this investigational drug (ION-682884) 45 mg subcutaneously every 4 weeks.
Description
Amyloid Cardiomyopathy
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyloid Cardiomyopathy
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- Patient with transthyretin-mediated amyloid cardiomyopathy who have been approved by the FDA and Indiana University IRB for single IND (compassionate use) of ION-682884.
Exclusion Criteria:
Updated on
27 Apr 2024.
Study ID: 11464, PATH-IIR-ION-682884-EA
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
